Media ReleasesImmutep

View All Immutep News

Immutep Announces Data Presentations at Upcoming Industry Conferences

SYDNEY, AUSTRALIA – October 24, 2018 – Immutep Limited (ASX:IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at several industry conferences in October, November and December, 2018.

Updated efficacy data from TACTI-mel is expected to be presented in an oral presentation at SITC.

For further information please download PDF attached:
Download this document